Katsiaryna Bykov, Sc.D., Pharm.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Interactions | 11 | 2021 | 1466 | 2.610 |
Why?
|
| Cross-Over Studies | 4 | 2020 | 2015 | 1.630 |
Why?
|
| Warfarin | 5 | 2023 | 1476 | 1.230 |
Why?
|
| Venous Thromboembolism | 3 | 2023 | 1582 | 1.150 |
Why?
|
| Analgesics, Opioid | 7 | 2022 | 3409 | 0.990 |
Why?
|
| Serotonin Uptake Inhibitors | 4 | 2017 | 1426 | 0.880 |
Why?
|
| Ticlopidine | 3 | 2017 | 884 | 0.850 |
Why?
|
| Anticoagulants | 6 | 2023 | 4375 | 0.830 |
Why?
|
| Oxycodone | 2 | 2022 | 140 | 0.830 |
Why?
|
| Rhabdomyolysis | 2 | 2019 | 157 | 0.810 |
Why?
|
| Pharmacoepidemiology | 2 | 2023 | 321 | 0.800 |
Why?
|
| Drug Evaluation | 2 | 2020 | 661 | 0.750 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2018 | 30 | 0.700 |
Why?
|
| Metoprolol | 1 | 2018 | 91 | 0.680 |
Why?
|
| Hemophilia B | 1 | 2017 | 81 | 0.630 |
Why?
|
| Pain, Postoperative | 5 | 2021 | 1629 | 0.630 |
Why?
|
| Urinary Tract Infections | 2 | 2022 | 780 | 0.630 |
Why?
|
| Factor VIIa | 1 | 2017 | 98 | 0.630 |
Why?
|
| Pyridones | 1 | 2022 | 692 | 0.620 |
Why?
|
| Antithrombins | 2 | 2019 | 302 | 0.610 |
Why?
|
| Cardiovascular Agents | 4 | 2015 | 837 | 0.600 |
Why?
|
| Drug Utilization | 3 | 2020 | 1236 | 0.600 |
Why?
|
| Epidemiologic Research Design | 1 | 2019 | 369 | 0.570 |
Why?
|
| Data Mining | 1 | 2021 | 552 | 0.570 |
Why?
|
| Blood Coagulation Factors | 1 | 2017 | 369 | 0.550 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2019 | 3149 | 0.540 |
Why?
|
| Hemophilia A | 1 | 2017 | 352 | 0.520 |
Why?
|
| Medication Adherence | 5 | 2018 | 2046 | 0.490 |
Why?
|
| Research Design | 4 | 2021 | 5902 | 0.480 |
Why?
|
| Myocardial Infarction | 6 | 2018 | 11403 | 0.470 |
Why?
|
| Electronic Health Records | 2 | 2019 | 4279 | 0.440 |
Why?
|
| Hemorrhage | 3 | 2019 | 3279 | 0.430 |
Why?
|
| Cohort Studies | 17 | 2023 | 40032 | 0.430 |
Why?
|
| Pyrazoles | 1 | 2022 | 1958 | 0.420 |
Why?
|
| Suicide | 1 | 2022 | 1573 | 0.410 |
Why?
|
| Thromboembolism | 1 | 2017 | 985 | 0.410 |
Why?
|
| Clarithromycin | 2 | 2020 | 79 | 0.370 |
Why?
|
| Azithromycin | 2 | 2022 | 188 | 0.370 |
Why?
|
| Fluoroquinolones | 2 | 2022 | 308 | 0.370 |
Why?
|
| Inpatients | 1 | 2021 | 2255 | 0.370 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 1073 | 0.360 |
Why?
|
| Hypoglycemic Agents | 2 | 2019 | 2774 | 0.360 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2019 | 112 | 0.350 |
Why?
|
| Databases, Factual | 11 | 2021 | 7901 | 0.340 |
Why?
|
| Insurance, Health | 2 | 2020 | 2497 | 0.330 |
Why?
|
| Cholesterol | 1 | 2016 | 2866 | 0.310 |
Why?
|
| Medicare | 2 | 2023 | 5791 | 0.300 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 1886 | 0.300 |
Why?
|
| Case-Control Studies | 4 | 2021 | 21795 | 0.300 |
Why?
|
| Treatment Failure | 1 | 2012 | 2677 | 0.300 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2016 | 3015 | 0.290 |
Why?
|
| Data Collection | 1 | 2015 | 3317 | 0.290 |
Why?
|
| Healthcare Disparities | 3 | 2016 | 3035 | 0.290 |
Why?
|
| Cerebral Hemorrhage | 2 | 2016 | 2587 | 0.280 |
Why?
|
| Propensity Score | 8 | 2020 | 1762 | 0.280 |
Why?
|
| Patient Readmission | 1 | 2018 | 2980 | 0.260 |
Why?
|
| United States | 15 | 2023 | 67910 | 0.260 |
Why?
|
| Baclofen | 2 | 2022 | 125 | 0.260 |
Why?
|
| Humans | 49 | 2023 | 715818 | 0.260 |
Why?
|
| Middle Aged | 24 | 2023 | 214666 | 0.250 |
Why?
|
| Parkinson Disease | 2 | 2016 | 2680 | 0.240 |
Why?
|
| Norfloxacin | 1 | 2022 | 21 | 0.240 |
Why?
|
| Carisoprodol | 1 | 2022 | 3 | 0.230 |
Why?
|
| Methocarbamol | 1 | 2022 | 7 | 0.230 |
Why?
|
| Drug Substitution | 2 | 2016 | 292 | 0.220 |
Why?
|
| Aged | 21 | 2023 | 162468 | 0.210 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 4881 | 0.210 |
Why?
|
| Paroxetine | 1 | 2022 | 171 | 0.210 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 5463 | 0.210 |
Why?
|
| Methods | 1 | 2021 | 1160 | 0.200 |
Why?
|
| Hospitalization | 6 | 2022 | 9745 | 0.200 |
Why?
|
| Lorazepam | 1 | 2021 | 142 | 0.200 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2015 | 1627 | 0.200 |
Why?
|
| Neuromuscular Agents | 1 | 2022 | 138 | 0.200 |
Why?
|
| Ciprofloxacin | 1 | 2022 | 317 | 0.200 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2015 | 498 | 0.200 |
Why?
|
| Stroke | 3 | 2017 | 9507 | 0.190 |
Why?
|
| Epidemiology | 1 | 2023 | 295 | 0.190 |
Why?
|
| Retrospective Studies | 9 | 2023 | 72473 | 0.190 |
Why?
|
| Control Groups | 1 | 2019 | 98 | 0.190 |
Why?
|
| Drug Therapy, Combination | 4 | 2020 | 6552 | 0.190 |
Why?
|
| Coronary Artery Bypass | 3 | 2015 | 2400 | 0.180 |
Why?
|
| Female | 28 | 2023 | 377229 | 0.180 |
Why?
|
| Drugs, Generic | 2 | 2016 | 520 | 0.180 |
Why?
|
| Male | 25 | 2022 | 350352 | 0.180 |
Why?
|
| Time Factors | 5 | 2022 | 40887 | 0.180 |
Why?
|
| Adult | 17 | 2023 | 212279 | 0.170 |
Why?
|
| Hospitals | 2 | 2022 | 3375 | 0.170 |
Why?
|
| Insurance Claim Review | 2 | 2021 | 750 | 0.170 |
Why?
|
| Postoperative Period | 2 | 2021 | 1844 | 0.170 |
Why?
|
| Simvastatin | 1 | 2020 | 361 | 0.160 |
Why?
|
| Fluoxetine | 1 | 2022 | 756 | 0.160 |
Why?
|
| Computer Simulation | 3 | 2020 | 6105 | 0.160 |
Why?
|
| Prescription Drugs | 2 | 2015 | 628 | 0.150 |
Why?
|
| Health Services | 1 | 2022 | 742 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 7095 | 0.150 |
Why?
|
| Names | 1 | 2015 | 53 | 0.140 |
Why?
|
| Aortic Aneurysm | 1 | 2020 | 665 | 0.140 |
Why?
|
| Aneurysm, Dissecting | 1 | 2020 | 641 | 0.140 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2015 | 127 | 0.140 |
Why?
|
| Ketorolac | 1 | 2015 | 69 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2015 | 2279 | 0.130 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 963 | 0.130 |
Why?
|
| Community Pharmacy Services | 1 | 2014 | 45 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2022 | 3955 | 0.120 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 1110 | 0.120 |
Why?
|
| Information Systems | 1 | 2015 | 390 | 0.120 |
Why?
|
| Risk Factors | 9 | 2021 | 70879 | 0.120 |
Why?
|
| Prevalence | 2 | 2021 | 14912 | 0.120 |
Why?
|
| Anti-Ulcer Agents | 1 | 2013 | 116 | 0.120 |
Why?
|
| Osteoarthritis, Hip | 1 | 2017 | 402 | 0.110 |
Why?
|
| Models, Theoretical | 2 | 2015 | 3579 | 0.110 |
Why?
|
| Thrombophilia | 1 | 2015 | 313 | 0.110 |
Why?
|
| Myocardial Revascularization | 1 | 2016 | 847 | 0.110 |
Why?
|
| Histamine H2 Antagonists | 1 | 2013 | 169 | 0.110 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 484 | 0.110 |
Why?
|
| Algorithms | 1 | 2012 | 13758 | 0.110 |
Why?
|
| Recurrence | 2 | 2022 | 8240 | 0.110 |
Why?
|
| Cephalosporins | 1 | 2013 | 218 | 0.110 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 12460 | 0.110 |
Why?
|
| Tamoxifen | 1 | 2016 | 992 | 0.110 |
Why?
|
| Logistic Models | 4 | 2020 | 13623 | 0.110 |
Why?
|
| Comorbidity | 3 | 2022 | 10435 | 0.100 |
Why?
|
| Financing, Personal | 1 | 2014 | 313 | 0.100 |
Why?
|
| Reminder Systems | 1 | 2014 | 388 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 803 | 0.100 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 263 | 0.100 |
Why?
|
| Emergency Medical Services | 1 | 2022 | 1794 | 0.100 |
Why?
|
| Neoplasms | 1 | 2019 | 20528 | 0.100 |
Why?
|
| Benzodiazepines | 3 | 2022 | 1085 | 0.090 |
Why?
|
| Treatment Outcome | 6 | 2019 | 62040 | 0.090 |
Why?
|
| Vancomycin | 1 | 2013 | 507 | 0.090 |
Why?
|
| African Americans | 2 | 2015 | 5003 | 0.090 |
Why?
|
| Proton Pump Inhibitors | 1 | 2013 | 480 | 0.090 |
Why?
|
| Sepsis | 1 | 2022 | 2465 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 3683 | 0.080 |
Why?
|
| Young Adult | 7 | 2020 | 56228 | 0.080 |
Why?
|
| Substance-Related Disorders | 2 | 2022 | 4183 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2015 | 2054 | 0.080 |
Why?
|
| Bone Density Conservation Agents | 1 | 2015 | 785 | 0.080 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 689 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 1536 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 628 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 6803 | 0.080 |
Why?
|
| Cesarean Section | 1 | 2016 | 1321 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2020 | 9985 | 0.080 |
Why?
|
| Pneumonia | 2 | 2020 | 2099 | 0.080 |
Why?
|
| Osteoarthritis, Knee | 1 | 2017 | 1197 | 0.080 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2017 | 1362 | 0.070 |
Why?
|
| Pain | 1 | 2022 | 4697 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 58326 | 0.070 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 1339 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 1687 | 0.070 |
Why?
|
| Patient Discharge | 1 | 2018 | 3030 | 0.070 |
Why?
|
| Emergency Service, Hospital | 2 | 2022 | 7499 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2015 | 2002 | 0.070 |
Why?
|
| Incidence | 3 | 2020 | 20733 | 0.070 |
Why?
|
| Risk | 1 | 2017 | 9799 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2016 | 1738 | 0.070 |
Why?
|
| Self Report | 1 | 2015 | 3416 | 0.060 |
Why?
|
| Seizures | 1 | 2016 | 2580 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 2032 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2019 | 5065 | 0.060 |
Why?
|
| Cross Infection | 1 | 2013 | 1407 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1498 | 0.060 |
Why?
|
| Orphenadrine | 1 | 2022 | 3 | 0.060 |
Why?
|
| Chlorzoxazone | 1 | 2022 | 5 | 0.060 |
Why?
|
| Hydrocodone | 1 | 2022 | 47 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2017 | 5030 | 0.060 |
Why?
|
| Depression | 1 | 2022 | 7268 | 0.060 |
Why?
|
| Amitriptyline | 1 | 2022 | 112 | 0.060 |
Why?
|
| Epilepsy | 1 | 2016 | 2922 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 7757 | 0.050 |
Why?
|
| Muscle Relaxants, Central | 1 | 2021 | 88 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2023 | 483 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2017 | 24796 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2017 | 41198 | 0.050 |
Why?
|
| Smoking | 2 | 2016 | 8980 | 0.050 |
Why?
|
| Prescriptions | 1 | 2022 | 347 | 0.050 |
Why?
|
| Risk Assessment | 6 | 2021 | 23476 | 0.050 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2021 | 458 | 0.040 |
Why?
|
| Adolescent | 5 | 2017 | 85157 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 39305 | 0.040 |
Why?
|
| Infant | 2 | 2017 | 34569 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2014 | 14438 | 0.040 |
Why?
|
| Narcotic Antagonists | 1 | 2022 | 553 | 0.040 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 4562 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2016 | 6447 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 5038 | 0.040 |
Why?
|
| Community Health Planning | 1 | 2016 | 162 | 0.040 |
Why?
|
| Etodolac | 1 | 2015 | 20 | 0.040 |
Why?
|
| Child | 3 | 2017 | 74468 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2015 | 273 | 0.030 |
Why?
|
| New Jersey | 1 | 2013 | 288 | 0.030 |
Why?
|
| Insurance Coverage | 2 | 2015 | 1863 | 0.030 |
Why?
|
| Hypnotics and Sedatives | 1 | 2021 | 1121 | 0.030 |
Why?
|
| Lactones | 1 | 2015 | 337 | 0.030 |
Why?
|
| Sulfones | 1 | 2015 | 457 | 0.030 |
Why?
|
| Peptic Ulcer | 1 | 2013 | 204 | 0.030 |
Why?
|
| Embolism | 1 | 2015 | 381 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1042 | 0.030 |
Why?
|
| Health Services Misuse | 1 | 2014 | 242 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2013 | 661 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1778 | 0.030 |
Why?
|
| Back Pain | 1 | 2016 | 548 | 0.030 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2014 | 348 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 465 | 0.030 |
Why?
|
| Telephone | 1 | 2014 | 631 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2013 | 15102 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 12483 | 0.020 |
Why?
|
| Age Distribution | 1 | 2016 | 2941 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 20062 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 1234 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2015 | 1510 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 2993 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 1482 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2013 | 939 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2016 | 1858 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2016 | 6495 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2013 | 1426 | 0.020 |
Why?
|
| Migraine Disorders | 1 | 2016 | 1575 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 2827 | 0.020 |
Why?
|
| Length of Stay | 1 | 2017 | 6270 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2015 | 51317 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2015 | 3317 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 11201 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 9596 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 27398 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 11090 | 0.010 |
Why?
|